Mallinckrodt, the financially troubled pharmaceutical company, is in discussions with a compensation trust for opioid victims as it seeks to potentially reduce the amount of settlement payments by as much as $1 billion, according to people familiar with the matter.
The generic drugmaker exited bankruptcy in 2022 with a $1.7 billion settlement agreement with state and local governments and private plaintiffs who alleged the company played a role in fueling the opioid crisis. It paid $450 million upon emergence from chapter…
